Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis - Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 Accéder directement au contenu
Article Dans Une Revue mAbs Année : 2019

Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis

Jerome Montharu
  • Fonction : Auteur
  • PersonId : 935615
Michele de Monte
  • Fonction : Auteur
  • PersonId : 935614

Résumé

Therapeutic antibodies (Abs) are emerging as major drugs to treat respiratory diseases, and inhalation may provide substantial benefits for their delivery. Understanding the behavior of Abs after pulmonary deposition is critical for their development. We investigated the pharmacokinetics of a nebulized Ab by continuous sampling in lung parenchyma using microdialysis in non-human primates. We defined the optimal conditions for microdialysis of Ab and demonstrated that lung microdialysis of Ab is feasible over a period of several days. The concentration-profile indicated a two-phase non-linear elimination and/or distribution of inhaled mAbX. Lung exposition was higher than the systemic one over a period of 33 hours and above MabX affinity for its target. The microdialysis results were supported by an excellent relationship with dosages from lung extracts.
Fichier principal
Vignette du fichier
10.1080-19420862.2018.1556081_Guillon et al 2019 (1).pdf (234.94 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02548918 , version 1 (03-06-2022)

Identifiants

Citer

Antoine Guillon, Jeoffrey Pardessus, Pierre Lhommet, Christelle Parent, Renaud Respaud, et al.. Exploring the fate of inhaled monoclonal antibody in the lung parenchyma by microdialysis. mAbs, 2019, 11 (2), pp.297-304. ⟨10.1080/19420862.2018.1556081⟩. ⟨hal-02548918⟩
62 Consultations
23 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More